Validate User
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your content.
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your content.
Key Points. CAR-T cell therapy demonstrates superior efficacy to bispecific antibody in DLBCL treatment, with higher complete response rates.CAR-T cell the
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe…
Arenas and colleagues report that patients with idiopathic multicentric Castleman disease display heightened activation of the mTOR signaling pathway, sugg
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe…
Key Points. This was a prospective long term follow-up study including 14530 PBSC and 7123 BM volunteer unrelated donors from the NMDP.PBSC and BM donors…
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon…
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
DDX41 germline mutations define the most common genetic syndrome predisposing to myeloid neoplasms (MN). Two papers highlight the genetic landscape and pro
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Key Points. Obinutuzumab can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in MCL patients.Obinutuzuma